<DOC>
	<DOCNO>NCT02649361</DOCNO>
	<brief_summary>To compare effect safety Anlotinib placebo patient esophageal squamous cell carcinoma ( ESCC ) .</brief_summary>
	<brief_title>Study Anlotinib Patients With Esophageal Squamous Cell Carcinoma ( ALTER1102 )</brief_title>
	<detailed_description />
	<mesh_term>Carcinoma</mesh_term>
	<mesh_term>Carcinoma , Squamous Cell</mesh_term>
	<mesh_term>Esophageal Neoplasms</mesh_term>
	<criteria>Histological documentation esophageal squamous cell carcinoma； Advanced esophageal squamous cell carcinoma distant metastasis ( Stage IV ) , least one measurable lesion ( RECIST1.1 ) Patients least fail platinumbased chemotherapy treatment chemotherapy contain paclitaxel . Note : ( 1 ) Each line treatment refers treatment duration least one cycle use monotherapy drug combination ; ( 2 ) Adjuvant chemotherapy neoadjuvant chemoradiation permit study ( disease recur adjuvant chemotherapy/neoadjuvant chemoradiation recur within 6 month stop treatment , adjuvant chemotherapy/neoadjuvant chemoradiation consider first line systemic chemotherapy ; 1875 year , ECOG PS:02 , Life expectancy 3 month 4 week last cytotoxic therapy , radiation therapy surgery Main organs function normal Women childbearing potential agree use utilize adequate method contraception ( intrauterine device，contraceptive condom ) throughout treatment least 6 month study stopped；the result serum urine pregnancy test negative within 7 day prior study enrollment，and patient require nonlactating；Man participant agree use utilize adequate method contraception throughout treatment least 6 month study stop Patients participate study voluntarily sign informed consent Patients whose primary lesion active bleeding within 2 month Primary lesion resect shrinked radiation therapy Patients failure antitumor angiogenesis drug treatment Patients factor could affect oral medication ( dysphagia，chronic diarrhea , intestinal obstruction etc . ) Brain metastasis patient symptom symptom control &lt; 3 month Patients severe and/or unable control diseases，including： 1 . Blood pressure unable control ideally ( systolic pressure≥150 mmHg，diastolic pressure≥100 mmHg ) ; 2 . Patients Grade 1 high myocardial ischemia , myocardial infarction malignant arrhythmia ( include QT≥480ms ) patient Grade 1 high congestive heart failure ( NYHA Classification ) ; 3 . Patients active unable control serious infection ; 4 . Patients cirrhosis , decompensated liver disease , active hepatitis ; 5 . Patients poorly control diabetes ( fast blood glucose ( FBG ) ＞10mmol/L ) 6 . Urine protein ≥ ++，and 24hour urinary protein excretion＞1.0 g confirm Patients nonhealing wound fracture Patients CTC AE Grade 1 high bleeding event occur lung CTC AE Grade 2 high bleeding event occur within 4 week prior assignment ; Patients physical sign bleed diathesis receive thrombolysis anticoagulation Patients arterial venous thromboembolic event occur within 6 month , cerebrovascular accident ( include transient ischemic attack ) , deep vein thrombosis pulmonary embolism Patients drug abuse history unable get rid Patients mental disorder Imaging show tumor involve important blood vessel investigator determine likely followup study cause fatal hemorrhage Patients participate anticancer drug clinical trial within 4 week History immunodeficiency Patients concomitant disease could seriously endanger safety could affect completion study accord investigator ' judgment</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>July 2016</verification_date>
	<keyword>Anlotinib</keyword>
</DOC>